Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eton Pharmaceuticals, Inc.ETON · Entity 4598 | Chief Business Officer | October 06, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eton Pharmaceuticals, Inc.
Report date October 06, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,381 |
Ending reported balance
After 2026-10-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-02 · Exercise / conversion · Acquired 10,522 · Balance 47,547 F3: On October 2, 2024, the reporting person was granted 42,088 restricted stock units which vest in four equal annual installments beginning October 2, 2025. Row 2 · 2026-10-06 · Sale · Disposed 4,166 · Balance 43,381 F1: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. F2: The shares were sold in multiple trades at prices ranging from $54.915 to $55.135. The price reported above reflects the weighted average sales price. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 21,044 |
Reported balance
After 2026-10-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-02 · Exercise / conversion · Disposed 10,522 · Balance 21,044 F3: On October 2, 2024, the reporting person was granted 42,088 restricted stock units which vest in four equal annual installments beginning October 2, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
F2: The shares were sold in multiple trades at prices ranging from $54.915 to $55.135. The price reported above reflects the weighted average sales price.
F3: On October 2, 2024, the reporting person was granted 42,088 restricted stock units which vest in four equal annual installments beginning October 2, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 6, 2026 20:49 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 4,166 | $55.07 | $229,406.21 |
DisclosureSEC source: 0001437749-26-032240 · rdgdoc.xml · nonDerivative · entry 2 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,381 F1 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. F2 · price: The shares were sold in multiple trades at prices ranging from $54.915 to $55.135. The price reported above reflects the weighted average sales price. Read SEC document |
| October 02, 2026 Filed Oct 6, 2026 20:49 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Exercise / conversionRestricted Stock Units · Derivative | 10,522 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-032240 · rdgdoc.xml · derivative · entry 3 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,044 Underlying: Common Stock · 10,522 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On October 2, 2024, the reporting person was granted 42,088 restricted stock units which vest in four equal annual installments beginning October 2, 2025. F3 · derivative.expiration_date: On October 2, 2024, the reporting person was granted 42,088 restricted stock units which vest in four equal annual installments beginning October 2, 2025. Read SEC document |
| October 02, 2026 Filed Oct 6, 2026 20:49 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Exercise / conversionCommon Stock | 10,522 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-032240 · rdgdoc.xml · nonDerivative · entry 1 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: On October 2, 2024, the reporting person was granted 42,088 restricted stock units which vest in four equal annual installments beginning October 2, 2025. Read SEC document |
| August 24, 2026 Filed Aug 24, 2026 21:19 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Exercise / conversionEmployee Stock Option · Derivative | 25,000 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0001437749-26-028846 · rdgdoc.xml · derivative · entry 3 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 25,000 shares Expires 2029-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option vested in 48 equal monthly installments from the date of grant (2-20-2019) until fully vested. Read SEC document |
| August 24, 2026 Filed Aug 24, 2026 21:19 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 25,000 | $65.07 | $1,626,750.00 |
DisclosureSEC source: 0001437749-26-028846 · rdgdoc.xml · nonDerivative · entry 2 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,025 F1 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. F2 · price: The shares were sold in multiple trades at prices ranging from $64.88 to $65.57. The price reported above reflects the weighted average sales price. Read SEC document |
| August 24, 2026 Filed Aug 24, 2026 21:19 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Exercise / conversionCommon Stock | 25,000 | $7.31 | $182,750.00 |
DisclosureSEC source: 0001437749-26-028846 · rdgdoc.xml · nonDerivative · entry 1 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 21:01 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantCommon Stock · Derivative | 128,985 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-025706 · rdgdoc.xml · derivative · entry 1 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,985 Underlying: Common Stock · 128,985 shares Expires not disclosed F1 · derivative.exercise_price: On July 31, 2026, the reporting person was granted 128,985 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range. F1 · derivative.exercise_date: On July 31, 2026, the reporting person was granted 128,985 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range. F1 · derivative.expiration_date: On July 31, 2026, the reporting person was granted 128,985 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range. Read SEC document |
| July 12, 2026 Filed Jul 13, 2026 20:36 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-023440 · rdgdoc.xml · derivative · entry 2 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On July 12, 2022, the reporting person was granted 40,000 restricted stock units which vested in four equal annual installments beginning July 12, 2023. F1 · derivative.expiration_date: On July 12, 2022, the reporting person was granted 40,000 restricted stock units which vested in four equal annual installments beginning July 12, 2023. Read SEC document |
| July 12, 2026 Filed Jul 13, 2026 20:36 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Exercise / conversionCommon Stock | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-023440 · rdgdoc.xml · nonDerivative · entry 1 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 12, 2022, the reporting person was granted 40,000 restricted stock units which vested in four equal annual installments beginning July 12, 2023. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 20:27 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-022154 · rdgdoc.xml · derivative · entry 1 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,829 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning June 26, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning June 26, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. Read SEC document |
| May 27, 2026 Filed May 27, 2026 22:28 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Exercise / conversionEmployee Stock Option · Derivative | 7,203 | $0.00 Strike: $3.58 | $0.00 |
DisclosureSEC source: 0001437749-26-018628 · rdgdoc.xml · derivative · entry 15 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,406 Underlying: Common Stock · 7,203 shares Expires 2030-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vested in 48 equal monthly installments from the date of grant (3-12-2020) until fully vested. Read SEC document |
| May 27, 2026 Filed May 27, 2026 22:28 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Exercise / conversionEmployee Stock Option · Derivative | 12,476 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001437749-26-018628 · rdgdoc.xml · derivative · entry 14 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,476 shares Expires 2027-11-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option vested annually from the date of grant (11-10-2017) in four equal installments. Read SEC document |
| May 27, 2026 Filed May 27, 2026 22:28 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 19,679 | $31.47 | $619,374.88 |
DisclosureSEC source: 0001437749-26-018628 · rdgdoc.xml · nonDerivative · entry 10 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,249 F1 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F5 · price: The shares were sold in multiple trades at prices ranging from $31.25 to $31.825. The price reported above reflects the weighted average sales price. Read SEC document |
| May 27, 2026 Filed May 27, 2026 22:28 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Exercise / conversionCommon Stock | 7,203 | $3.58 | $25,786.74 |
DisclosureSEC source: 0001437749-26-018628 · rdgdoc.xml · nonDerivative · entry 9 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 27, 2026 Filed May 27, 2026 22:28 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Exercise / conversionCommon Stock | 12,476 | $1.37 | $17,092.12 |
DisclosureSEC source: 0001437749-26-018628 · rdgdoc.xml · nonDerivative · entry 8 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2026 Filed May 27, 2026 22:28 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Exercise / conversionEmployee Stock Option · Derivative | 12,524 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001437749-26-018628 · rdgdoc.xml · derivative · entry 13 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,476 Underlying: Common Stock · 12,524 shares Expires 2027-11-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option vested annually from the date of grant (11-10-2017) in four equal installments. Read SEC document |
| May 26, 2026 Filed May 27, 2026 22:28 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Exercise / conversionEmployee Stock Option · Derivative | 25,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001437749-26-018628 · rdgdoc.xml · derivative · entry 12 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2027-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The shares subject to option vested annually from the date of grant (8-7-2017) in four equal installments. Read SEC document |
| May 26, 2026 Filed May 27, 2026 22:28 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 37,524 | $31.49 | $1,181,732.07 |
DisclosureSEC source: 0001437749-26-018628 · rdgdoc.xml · nonDerivative · entry 7 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,249 F1 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · price: The shares were sold in multiple trades at prices ranging from $31.27 to $32.16. The price reported above reflects the weighted average sales price. Read SEC document |
| May 26, 2026 Filed May 27, 2026 22:28 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Exercise / conversionCommon Stock | 12,524 | $1.37 | $17,157.88 |
DisclosureSEC source: 0001437749-26-018628 · rdgdoc.xml · nonDerivative · entry 6 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,773 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2026 Filed May 27, 2026 22:28 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Exercise / conversionCommon Stock | 25,000 | $1.38 | $34,500.00 |
DisclosureSEC source: 0001437749-26-018628 · rdgdoc.xml · nonDerivative · entry 5 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,249 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2026 Filed May 27, 2026 22:28 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Exercise / conversionEmployee Stock Option · Derivative | 30,591 | $0.00 Strike: $3.58 | $0.00 |
DisclosureSEC source: 0001437749-26-018628 · rdgdoc.xml · derivative · entry 11 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,609 Underlying: Common Stock · 30,591 shares Expires 2030-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vested in 48 equal monthly installments from the date of grant (3-12-2020) until fully vested. Read SEC document |
| May 22, 2026 Filed May 27, 2026 22:28 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 519 | $35.00 | $18,165.00 |
DisclosureSEC source: 0001437749-26-018628 · rdgdoc.xml · nonDerivative · entry 4 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,249 Read SEC document |
| May 22, 2026 Filed May 27, 2026 22:28 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 9,315 | $33.88 | $315,594.06 |
DisclosureSEC source: 0001437749-26-018628 · rdgdoc.xml · nonDerivative · entry 3 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,768 F1 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F2 · price: The shares were sold in multiple trades at prices ranging from $33.68 to $34.66. The price reported above reflects the weighted average sales price. Read SEC document |
| May 22, 2026 Filed May 27, 2026 22:28 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 32,963 | $33.22 | $1,095,057.23 |
DisclosureSEC source: 0001437749-26-018628 · rdgdoc.xml · nonDerivative · entry 2 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,083 F1 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F7 · price: The shares were sold in multiple trades at prices ranging from $32.67 to $33.65. The price reported above reflects the weighted average sales price. Read SEC document |
| May 22, 2026 Filed May 27, 2026 22:28 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Exercise / conversionCommon Stock | 30,591 | $3.58 | $109,515.78 |
DisclosureSEC source: 0001437749-26-018628 · rdgdoc.xml · nonDerivative · entry 1 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 14, 2026 Filed Jan 14, 2026 23:03 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Tax withholdingCommon Stock | 1,942 | $15.62 | $30,334.04 |
DisclosureSEC source: 0001437749-26-001288 · rdgdoc.xml · nonDerivative · entry 1 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 630,238 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of restricted stock units. F2 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 23:03 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantRestricted Stock Units · Derivative | 25,856 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-001288 · rdgdoc.xml · derivative · entry 3 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 696,749 Underlying: Common Stock · 25,856 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock. F5 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. F5 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 23:03 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantEmployee Stock Option (Right to Buy) · Derivative | 40,655 | $0.00 Strike: $15.47 | $0.00 |
DisclosureSEC source: 0001437749-26-001288 · rdgdoc.xml · derivative · entry 2 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 670,893 Underlying: Common Stock · 40,655 shares Expires 2036-01-11 F3 · derivative.exercise_date: The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on January 12, 2030. Read SEC document |
| December 12, 2025 Filed Dec 12, 2025 21:56 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Tax withholdingCommon Stock | 6,264 | $17.00 | $106,488.00 |
DisclosureSEC source: 0001437749-25-037745 · rdgdoc.xml · nonDerivative · entry 1 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 632,180 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of restricted stock units. F2 · price: The shares were sold in multiple trades at prices ranging from $16.83 to $17.11. The price reported above reflects the weighted average sales price. F3 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| December 11, 2025 Filed Dec 12, 2025 21:56 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantRestricted Stock Units · Derivative | 5,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-037745 · rdgdoc.xml · derivative · entry 2 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 638,468 Underlying: Common Stock · 5,300 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock. F5 · derivative.exercise_date: The restricted stock units vest immediately as of the award date. F5 · derivative.expiration_date: The restricted stock units vest immediately as of the award date. Read SEC document |
| June 16, 2025 Filed Jun 16, 2025 20:56 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 10,223 | $14.73 | $150,584.79 |
DisclosureSEC source: 0001437749-25-020518 · rdgdoc.xml · nonDerivative · entry 3 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 612,646 F3 · price: The shares were sold in multiple trades at prices ranging from $14.50 to $14.79. The price reported above reflects the weighted average sales price. F4 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 13, 2025 Filed Jun 16, 2025 20:56 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 6,800 | $14.77 | $100,436.00 |
DisclosureSEC source: 0001437749-25-020518 · rdgdoc.xml · nonDerivative · entry 2 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 622,869 F2 · price: The shares were sold in multiple trades at prices ranging from $14.75 to $14.81. The price reported above reflects the weighted average sales price. F4 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:56 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 16,977 | $14.92 | $253,296.84 |
DisclosureSEC source: 0001437749-25-020518 · rdgdoc.xml · nonDerivative · entry 1 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 629,669 F1 · price: The shares were sold in multiple trades at prices ranging from $14.77 to $14.98. The price reported above reflects the weighted average sales price. F4 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 03, 2025 Filed Jan 6, 2025 21:16 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantRestricted Stock Units · Derivative | 25,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-000455 · rdgdoc.xml · derivative · entry 2 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,876 Underlying: Common Stock · 25,876 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 3, 2026, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 3, 2026, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. Read SEC document |
| January 03, 2025 Filed Jan 6, 2025 21:16 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantEmployee Stock Option (Right to Buy) · Derivative | 38,621 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001437749-25-000455 · rdgdoc.xml · derivative · entry 1 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,621 Underlying: Common Stock · 38,621 shares Expires 2035-01-02 F1 · derivative.exercise_date: The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on January 3, 2029. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 20:19 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantRestricted Stock Units · Derivative | 42,088 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-030714 · rdgdoc.xml · derivative · entry 1 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 861,374 Underlying: Common Stock · 42,088 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning October 2, 2025, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning October 2, 2025, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:17 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantStock Option (Right to buy) · Derivative | 144,677 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0001437749-24-004361 · rdgdoc.xml · derivative · entry 1 Krempa David · CIK 0001968254 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 813,430 Underlying: Common Stock · 144,677 shares Expires 2034-02-12 F1 · derivative.exercise_date: The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on February 13, 2028. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.